Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Core Viewpoint - Ernexa Therapeutics announced a reverse stock split at a ratio of 1-for-15 to comply with Nasdaq's minimum bid price requirement for continued listing [1][2][7] Group 1: Reverse Stock Split Details - The reverse stock split will take effect on June 12, 2025, at 12:01 a.m. Eastern Time, with trading on a split-adjusted basis commencing the same day [1] - Every 15 shares of Common Stock will be reclassified into one new share, with no modification to the rights or preferences of the shares [2] - The company had 110,418,022 shares outstanding prior to the split, which will reduce to approximately 7,361,201 shares post-split [4] Group 2: Shareholder Impact - No fractional shares will be issued; stockholders will receive one whole share instead of fractional shares [3] - Stockholders holding pre-split certificates will receive instructions from Computershare on how to surrender their certificates [5] Group 3: Company Background and Strategy - Ernexa Therapeutics focuses on developing innovative stem cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells [8] - The company’s lead product, ERNA-101, aims to activate the immune system against cancer cells, with an initial focus on ovarian cancer [9][10] - The reverse stock split is part of a broader strategy to strengthen the company's financial foundation and maintain access to capital markets for advancing clinical programs [7]